{"entity":{"type":"insider","cik":"0001363984","url":"/insider/0001363984","json_url":"/insider/0001363984.json","name":"Maynard Ryan D","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":12,"n_filings":8,"first":"2012-08-09","last":"2024-11-14","span_basis":"filed_date"},"name_variants":[{"name":"Maynard Ryan D","source":"filing","n_filings":8,"first_seen":"2012-08-09","last_seen":"2024-11-14"}],"transactions":[{"id":2623715,"accession":"0001104659-24-119195","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-24-119195","line_url":"/filing/0001104659-24-119195#line-2","is_derivative":false,"issuer_cik":"0001363984","issuer_name":"IOVANCE BIOTHERAPEUTICS, INC.","issuer_ticker":"IOVA","issuer_name_source":null,"issuer_url":"/issuer/0001363984","owner_cik":"0001363984","owner_name":"Maynard Ryan D","owner_display_name":"Maynard Ryan D","owner_url":"/insider/0001363984","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50000.0,"shares_display":"50,000","price_per_share":10.06,"price_display":"10.06","price_state":"stated","total_value":503000.0,"total_display":"503,000.00","total_whole":"503,000","shares_owned_after":7500.0,"shares_owned_after_display":"7,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-12","filed_date":"2024-11-14","scope":"insider"},{"id":3052525,"accession":"0001415889-24-003404","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-24-003404","line_url":"/filing/0001415889-24-003404#line-1","is_derivative":false,"issuer_cik":"0001346830","issuer_name":"Cara Therapeutics, Inc.","issuer_ticker":"CARA","issuer_name_source":null,"issuer_url":"/issuer/0001346830","owner_cik":"0001363984","owner_name":"Maynard Ryan D","owner_display_name":"Maynard Ryan D","owner_url":"/insider/0001363984","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5488.0,"shares_display":"5,488","price_per_share":0.53,"price_display":"0.53","price_state":"stated","total_value":2908.64,"total_display":"2,908.64","total_whole":"2,909","shares_owned_after":8012.0,"shares_owned_after_display":"8,012","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-08","filed_date":"2024-02-12","scope":"insider"},{"id":6214665,"accession":"0001104659-22-067762","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-22-067762","line_url":"/filing/0001104659-22-067762#line-1","is_derivative":false,"issuer_cik":"0001363984","issuer_name":"IOVANCE BIOTHERAPEUTICS, INC.","issuer_ticker":"IOVA","issuer_name_source":null,"issuer_url":"/issuer/0001363984","owner_cik":"0001363984","owner_name":"Maynard Ryan D","owner_display_name":"Maynard Ryan D","owner_url":"/insider/0001363984","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7500.0,"shares_display":"7,500","price_per_share":6.745,"price_display":"6.74","price_state":"stated","total_value":50587.5,"total_display":"50,587.50","total_whole":"50,588","shares_owned_after":7500.0,"shares_owned_after_display":"7,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-05-31","filed_date":"2022-06-02","scope":"insider"},{"id":4932029,"accession":"0001179110-17-013850","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001179110-17-013850","line_url":"/filing/0001179110-17-013850#line-2","is_derivative":false,"issuer_cik":"0001034842","issuer_name":"RIGEL PHARMACEUTICALS INC","issuer_ticker":"RIGL","issuer_name_source":null,"issuer_url":"/issuer/0001034842","owner_cik":"0001363984","owner_name":"Maynard Ryan D","owner_display_name":"Maynard Ryan D","owner_url":"/insider/0001363984","role":"Officer (EVP & CFO)","role_mark":"O","role_mark_label":"Officer (EVP & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100000.0,"shares_display":"100,000","price_per_share":3.9,"price_display":"3.90","price_state":"stated","total_value":390000.0,"total_display":"390,000.00","total_whole":"390,000","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-11-03","filed_date":"2017-11-07","scope":"insider"},{"id":9241939,"accession":"0001179110-12-014077","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001179110-12-014077","line_url":"/filing/0001179110-12-014077#line-1","is_derivative":false,"issuer_cik":"0001034842","issuer_name":"RIGEL PHARMACEUTICALS INC","issuer_ticker":"RIGL","issuer_name_source":null,"issuer_url":"/issuer/0001034842","owner_cik":"0001363984","owner_name":"Maynard Ryan D","owner_display_name":"Maynard Ryan D","owner_url":"/insider/0001363984","role":"Officer (EVP & CFO)","role_mark":"O","role_mark_label":"Officer (EVP & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":23302.0,"shares_display":"23,302","price_per_share":10.6669,"price_display":"10.67","price_state":"stated","total_value":248560.1038,"total_display":"248,560.10","total_whole":"248,560","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-09-12","filed_date":"2012-09-14","scope":"insider"},{"id":2952407,"accession":"0001179110-12-013911","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001179110-12-013911","line_url":"/filing/0001179110-12-013911#line-4","is_derivative":false,"issuer_cik":"0001034842","issuer_name":"RIGEL PHARMACEUTICALS INC","issuer_ticker":"RIGL","issuer_name_source":null,"issuer_url":"/issuer/0001034842","owner_cik":"0001363984","owner_name":"Maynard Ryan D","owner_display_name":"Maynard Ryan D","owner_url":"/insider/0001363984","role":"Officer (EVP & CFO)","role_mark":"O","role_mark_label":"Officer (EVP & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":17586.0,"shares_display":"17,586","price_per_share":10.5156,"price_display":"10.52","price_state":"stated","total_value":184927.3416,"total_display":"184,927.34","total_whole":"184,927","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-09-10","filed_date":"2012-09-11","scope":"insider"},{"id":2952433,"accession":"0001179110-12-014072","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001179110-12-014072","line_url":"/filing/0001179110-12-014072#line-2","is_derivative":false,"issuer_cik":"0001034842","issuer_name":"RIGEL PHARMACEUTICALS INC","issuer_ticker":"RIGL","issuer_name_source":null,"issuer_url":"/issuer/0001034842","owner_cik":"0001363984","owner_name":"Maynard Ryan D","owner_display_name":"Maynard Ryan D","owner_url":"/insider/0001363984","role":"Officer (EVP & CFO)","role_mark":"O","role_mark_label":"Officer (EVP & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":23302.0,"shares_display":"23,302","price_per_share":10.6669,"price_display":"10.67","price_state":"stated","total_value":248560.1038,"total_display":"248,560.10","total_whole":"248,560","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-09-07","filed_date":"2012-09-14","scope":"insider"},{"id":2952399,"accession":"0001179110-12-013911","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001179110-12-013911","line_url":"/filing/0001179110-12-013911#line-2","is_derivative":false,"issuer_cik":"0001034842","issuer_name":"RIGEL PHARMACEUTICALS INC","issuer_ticker":"RIGL","issuer_name_source":null,"issuer_url":"/issuer/0001034842","owner_cik":"0001363984","owner_name":"Maynard Ryan D","owner_display_name":"Maynard Ryan D","owner_url":"/insider/0001363984","role":"Officer (EVP & CFO)","role_mark":"O","role_mark_label":"Officer (EVP & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":34112.0,"shares_display":"34,112","price_per_share":10.5523,"price_display":"10.55","price_state":"stated","total_value":359960.0576,"total_display":"359,960.06","total_whole":"359,960","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-09-07","filed_date":"2012-09-11","scope":"insider"},{"id":2606038,"accession":"0001179110-12-012641","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001179110-12-012641","line_url":"/filing/0001179110-12-012641","is_derivative":false,"issuer_cik":"0001034842","issuer_name":"RIGEL PHARMACEUTICALS INC","issuer_ticker":"RIGL","issuer_name_source":null,"issuer_url":"/issuer/0001034842","owner_cik":"0001363984","owner_name":"Maynard Ryan D","owner_display_name":"Maynard Ryan D","owner_url":"/insider/0001363984","role":"Officer (EVP & CFO)","role_mark":"O","role_mark_label":"Officer (EVP & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1700.0,"shares_display":"1,700","price_per_share":10.612058823529411,"price_display":"10.61","price_state":"stated","total_value":18040.5,"total_display":"18,040.50","total_whole":"18,041","shares_owned_after":1000.0,"shares_owned_after_display":"1,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-08-07","filed_date":"2012-08-09","scope":"insider","n_lines":4}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":12,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":1,"open_market":true},{"code":"S","label":"Open-market sale","n":11,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":12},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001425205","name":"IOVANCE BIOTHERAPEUTICS, INC.","url":"/issuer/0001425205","role":"Director","n_filings":2,"first_seen":"2022-06-02","last_seen":"2024-11-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001346830","name":"Cara Therapeutics, Inc.","url":"/issuer/0001346830","role":"Officer (CHIEF FINANCIAL OFFICER)","n_filings":1,"first_seen":"2024-02-12","last_seen":"2024-02-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001034842","name":"RIGEL PHARMACEUTICALS INC","url":"/issuer/0001034842","role":"Officer (EVP & CFO)","n_filings":5,"first_seen":"2012-08-09","last_seen":"2017-11-07"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001363984","retrieved_at":"2026-08-26T09:35:38+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}